Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Zhen, Anjie ^a   Du, Juan ^b   Zhou, Xiaohong ^a,b   Xiong, Yong ^c   Yu, Xiao Fang ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JILIN UNIVERSITY   (China)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; CYTIDINE DEAMINASE; PROTEIN; UNCLASSIFIED DRUG;

A3H GENE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE; HAPLOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PROTEIN FAMILY; PROTEIN MOTIF; RNA BINDING; RNA STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINOHYDROLASES; BINDING SITES; CONSERVED SEQUENCE; HAPLOTYPES; HEK293 CELLS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN TRANSPORT; RNA, SMALL CYTOPLASMIC; SIGNAL RECOGNITION PARTICLE; VIRION; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864456753     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038771     Document Type: Article

References (55)

1. Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, et al. ((2006)) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A 103:: 15588--15593.
2. Conticello SG, ((2008)) The AID/APOBEC family of nucleic acid mutators. Genome Biol 9:: 229.
3. Goila-Gaur R, Strebel K, ((2008)) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:: 51.
4. Kinomoto M, Kanno T, Shimura M, Ishizaka Y, Kojima A, et al. ((2007)) All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res 35:: 2955--2964.
5. Malim MH, ((2006)) Natural resistance to HIV infection: The Vif-APOBEC interaction. C R Biol 329:: 871--875.
6. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, et al. ((2006)) APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 281:: 22161--22172.
7. Harris RS, Liddament MT, ((2004)) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4:: 868--877.
8. Conticello SG, Harris RS, Neuberger MS, ((2003)) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13:: 2009--2013.
9. Cullen BR, ((2003)) HIV-1 Vif: counteracting innate antiretroviral defenses. Mol Ther 8:: 525--527.
10. Larue RS, Lengyel J, Jonsson SR, Andresdottir V, Harris RS, ((2010)) Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol 84:: 8193--8201.
11. Marin M, Rose KM, Kozak SL, Kabat D, ((2003)) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:: 1398--1403.
12. Sheehy AM, Gaddis NC, Malim MH, ((2003)) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:: 1404--1407.
13. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. ((2003)) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:: 1056--1060.
14. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF, ((2010)) A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol 84:: 1902--1911.
15. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, et al. ((2009)) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83:: 494--497.
16. OhAinle M, Kerns JA, Malik HS, Emerman M, ((2006)) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol 80:: 3853--3862.
17. Harari A, Ooms M, Mulder LC, Simon V, ((2009)) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 83:: 295--303.
18. Tan L, Sarkis PT, Wang T, Tian C, Yu XF, ((2009)) Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J 23:: 279--287.
19. LaRue RS, Jonsson SR, Silverstein KA, Lajoie M, Bertrand D, et al. ((2008)) The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol 9:: 104.
20. Dang Y, Siew LM, Wang X, Han Y, Lampen R, et al. ((2008)) Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 283:: 11606--11614.
21. Dang Y, Wang X, Esselman WJ, Zheng YH, ((2006)) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80:: 10522--10533.
22. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M, ((2008)) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4:: 249--259.
23. Ooms M, Majdak S, Seibert CW, Harari A, Simon V, ((2010)) The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J Virol 84:: 7961--7969.
24. An P, Duggal P, Wang LH, O'Brien SJ, Donfield S, et al. ((2007)) Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 3:: e19.
25. Alce TM, Popik W, ((2004)) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 279:: 34083--34086.
26. Schafer A, Bogerd HP, Cullen BR, ((2004)) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:: 163--168.
27. Wang T, Tian C, Zhang W, Luo K, Sarkis PT, et al. ((2007)) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol 81:: 13112--13124.
28. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD, ((2004)) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 78:: 12058--12061.
29. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, et al. ((2004)) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279:: 33177--33184.
30. Luo K, Liu B, Xiao Z, Yu Y, Yu X, et al. ((2004)) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 78:: 11841--11852.
31. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, et al. ((2005)) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 79:: 5870--5874.
32. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. ((2004)) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279:: 35822--35828.
33. Wang T, Tian C, Zhang W, Sarkis PT, Yu XF, ((2008)) Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J Mol Biol 375:: 1098--1112.
34. Onafuwa-Nuga AA, Telesnitsky A, King SR, ((2006)) 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. RNA 12:: 542--546.
35. Zhang W, Du J, Yu K, Wang T, Yong X, et al. ((2010)) Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J Virol 84:: 12903--12913.
36. Wang X, Abudu A, Son S, Dang Y, Venta PJ, et al. ((2011)) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol 85:: 3142--3152.
37. Sali A, Blundell TL, ((1993)) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:: 779--815.
38. Zhang W, Huang M, Wang T, Tan L, Tian C, et al. ((2008)) Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol 10:: 1662--1675.
39. Battey JN, Kopp J, Bordoli L, Read RJ, Clarke ND, et al. ((2007)) Automated server predictions in CASP7. Proteins 69 Suppl 8: 68--82.
40. Edgar RC, ((2004)) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:: 1792--1797.
41. Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS, ((2007)) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445:: 447--451.
42. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, et al. ((2008)) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456:: 121--124.
43. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, et al. ((2008)) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452:: 116--119.
44. Bach D, Peddi S, Mangeat B, Lakkaraju A, Strub K, et al. ((2008)) Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 5:: 54.
45. Wang T, Zhang W, Tian C, Liu B, Yu Y, et al. ((2008)) Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology 377:: 71--79.
46. Gourraud PA, Karaouni A, Woo JM, Schmidt T, Oksenberg JR, et al. ((2010)) APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum Immunol 72:: 207--212.
47. Li MM, Emerman M, ((2011)) Polymorphism in Human APOBEC3H Affects a Phenotype Dominant for Subcellular Localization and Antiviral Activity. J Virol 85:: 8197--8207.
48. Bieniasz PD, ((2004)) Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 5:: 1109--1115.
49. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. ((2004)) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14:: 1392--1396.
50. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, et al. ((2006)) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A 103:: 8780--8785.
51. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, et al. ((2006)) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16:: 480--485.
52. Bennett RP, Presnyak V, Wedekind JE, Smith HC, ((2008)) Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J Biol Chem 283:: 7320--7327.
53. Burnett A, Spearman P, ((2007)) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J Virol 81:: 5000--5013.
54. Marin M, Golem S, Rose KM, Kozak SL, Kabat D, ((2008)) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol 82:: 987--998.
55. Stenglein MD, Matsuo H, Harris RS, ((2008)) Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol 82:: 9591--9599.